PE-backed companies fail on portfolio leverage. Not product. Leverage.

Your product execution is solid. Revenue is real. But marketing metrics sit below investor targets. Buyer committee friction stalls deals. Cross-portco standardization never happened. Your sponsor wants investor-ready metrics. You need operational leverage and CMO-level strategy that scales.

Built for CMO or Head of Marketing at PE-backed portfolio company, $50M-$500M+ revenue. For portfolio companies executing operationally well but hitting investor questions on marketing ROI, deal velocity, and buyer committee alignment.

Full Diagnostic
$15K-$25K

Three to four weeks from intake to delivery

Tier: SF-4 / Escalates to SF-5 Fractional CMO

Start Diagnostic
Diagnostic sets up fractional CMO engagement ($15K-$20K/month, 6-12 months). Many PE portcos run diagnostic first, then CMO for execution.

PE portfolio companies sit in a leverage trap. The product works. Revenue grows. Execution is clean. But marketing is a patchwork from prior ownership, your CAC payback doesn't match investor targets, your buyer committee objections persist across similar deals, and you can't translate your metrics into the portfolio playbook. The diagnostic maps your operational leverage points, translates your metrics into investor language, and builds a roadmap for cross-portco standardization that works within your PE ownership model.

Your Buying Committee

You (CMO/Head of Marketing)

Running marketing in a PE-owned company means delivering investor-ready metrics and positioning the business for the next lever or exit. You own go-to-market, buyer committee dynamics, and CAC payback. Investor pressure is real.

CFO / Chief Financial Officer

Owns the investor reporting and EBITDA model. Cares about CAC payback, LTV multiples, and whether marketing spend is justified. Needs to show investor sponsors that marketing is a leverage point, not a cost drain.

Chief Revenue Officer (if present)

Manages deal velocity and buyer committee friction. Sales has clear lead SLAs but buyer committee objections are slowing closes. Wants marketing to address the objections that lose deals, not just feed sales leads.

PE Sponsor / Portfolio Partner

Sees this portco against the portfolio. Wants operational leverage across sister companies, investor-ready metrics, and CMO capability that scales as revenue scales. Cares about standardization and succession planning.

The Dominant Metric

42%
Average deal velocity improvement across 11 PE portfolio companies post-CMO diagnostic and buyer committee mapping. 34-week sales cycle compressed to 20 weeks. CAC payback from 18 months to 11 months. Investor satisfaction on marketing governance improved from 3.2/5 to 4.6/5 on annual LP surveys.

Where PE Portco Marketing Breaks

Buyer Committee Economics Mismatch

Your marketing story sells to the practitioner. But the compliance officer, budget owner, and risk officer on the buyer committee have different friction points. Sales team doesn't have language to move the committee. Deals stall in legal or procurement.

CAC Payback Disconnected from Investor Model

You report CAC payback to your sponsor. But your metrics don't align to the investor's playbook or sister companies' metrics. Sponsor can't see your performance against the portfolio. Can't justify marketing spend to LPs. Can't model the lever into the exit.

Cross-Portco Leverage Unrealized

Your sponsor owns 4-7 sister companies. Each one runs its own marketing stack, its own lead definitions, its own buyer committee approach. Zero sharing of playbooks, zero standardization of metrics, zero talent mobility. You're rebuilding the wheel for every portco.

What the Diagnostic Covers

  1. Portfolio Context & Investor Model Audit, We map your sponsor's investment strategy, exits on the portfolio, investor metrics they're tracking, and where your company sits in the portfolio landscape. This sets the frame for everything downstream.
  2. Current-State Marketing Audit, Attribution model, lead definitions, buyer committee mapping, sales-marketing handoff, tech stack audit, vendor relationships, cost structure. What's working. What's bolted on.
  3. Buyer Committee Positioning Analysis, Who is on the actual committee? What are their objections? Which ones create deal friction? How do you translate your positioning into language that moves each role?
  4. Cross-Portco Standardization Roadmap, If your sponsor owns multiple companies, how do you align metrics, lead definitions, and buyer committee approach without forcing one-size-fits-all? What can be shared? What stays local?
  5. 90-Day Execution Roadmap, Three outcomes: investor-ready metrics, buyer committee language, and fractional CMO handoff if you want to escalate to ongoing strategy and execution.

Proof: PE Portfolio Company $180M ARR

Case: Software acquirer, three recent bolt-on acquisitions

The parent company acquired three smaller B2B software companies in 12 months. Each one had a $20-60M revenue run. Each one ran its own marketing, three agencies, three attribution models, three definitions of a qualified lead. Investor sponsor wanted consolidated metrics, marketing leverage across the platform, and CMO-level strategy for exits.

Sales cycle compression 29 weeks → 17 weeks (-41%)
CAC payback improvement 20 months → 12 months (-40%)
Buyer committee objections 7.2 avg per deal → 2.1 avg (-71%)
Investor satisfaction 3.4/5 baseline → 4.7/5 post-implementation
Cross-portco playbook adoption 0% to 89% of sister companies aligned on metrics

What to Expect

The Process

You get three intake calls: one with marketing, one with the CFO or investor sponsor to frame metrics and model, one with the CRO to stress-test buyer committee positioning. Then a week of audit and mapping. Then two weeks of strategy and roadmap. Then a delivery presentation to your executive team and sponsor.

Every recommendation has a clear investor angle and an execution path. Nothing stays theoretical. Everything gets operationalized into next steps.

The founder, whose broader work is at stantscherenkow.com, leads every engagement. The strategy does not leave the room.

Good Fit / Not a Fit

Good Fit for This Diagnostic

  • PE-backed, Series B-C equivalent, $50M-$500M+ revenue
  • Product execution and revenue are solid. Marketing metrics are the question.
  • You have a CMO or marketing leader. You need strategy and investor leverage.
  • You're willing to revisit metrics and buyer committee positioning.
  • Your sponsor expects this work and will act on recommendations.

Not a Fit

  • You're a product-stage company under $50M revenue. Try SF-3 Strategic Intervention instead.
  • You want to hire an internal CMO and need recruiting help. That's a different scope.
  • You're looking to replace your agency. We audit and strategize; we don't execute the day-to-day.
  • Your sponsor is hands-off and won't use the investor metrics. The leverage disappears.
  • You're 12+ months from exit. This advisory is for portcos with a 2-3 year runway.

What 90 Days Looks Like

  1. Investor-Ready Metrics Clarity, Your CAC payback, LTV multiple, buyer committee friction, and deal velocity translate into your sponsor's playbook. The investor can see your marketing as a leverage point.
  2. Buyer Committee Language Playbook, You know which roles create friction, what each one needs to hear, and how to translate your positioning so the committee moves instead of stalls.
  3. Cross-Portco Standardization Started, If relevant, you have a 12-month roadmap to align metrics and playbooks across sister companies. Execution starts internally.
  4. CMO Escalation Decision, You decide: hire an internal CMO and execute on the roadmap, or bring in fractional CMO for six to twelve months to implement while you build the team.
  5. Board Conversation Readiness, You have a clean narrative for your investor sponsor and board: where marketing has been, why buyer committee friction exists, what changes, and what the next 12 months delivers.
  6. Exit Positioning Started, If on a multi-year exit path, your marketing story and metrics now support a stronger narrative for acquirers. Inbound starts earlier because your positioning is clearer.

Get Started

Tell us about your portfolio company. We'll schedule a 20-minute call to confirm fit, discuss your investor model, and scope the diagnostic.